|Bid||33.01 x 800|
|Ask||42.51 x 900|
|Day's Range||39.60 - 40.70|
|52 Week Range||19.35 - 43.90|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020 - Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.64|
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced four poster presentations at the 35th Annual Meeting of the Society for Immunotherapy of Cancer, being held virtually November 9-14, 2020.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress. […]
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced initial data from its ongoing Phase 1 study of tidutamab (XmAb®18087), an SSTR2 x CD3 bispecific antibody, in patients with neuroendocrine tumors (NETs). The data were presented at the North American Neuroendocrine Tumor Society’s 2020 Multidisciplinary NET Medical Virtual Symposium (NANETS).